{"log_id": 3966280316383637397, "direction": 0, "words_result_num": 36, "words_result": [{"probability": {"variance": 5.6e-05, "average": 0.989455, "min": 0.98196}, "location": {"width": 78, "top": 147, "height": 23, "left": 220}, "words": "药理作用"}, {"probability": {"variance": 0, "average": 0.841099, "min": 0.841099}, "location": {"width": 24, "top": 123, "height": 79, "left": 1102}, "words": "一"}, {"probability": {"variance": 7e-06, "average": 0.995888, "min": 0.992584}, "location": {"width": 83, "top": 185, "height": 24, "left": 215}, "words": "微生物学"}, {"probability": {"variance": 1e-06, "average": 0.997597, "min": 0.996452}, "location": {"width": 83, "top": 223, "height": 25, "left": 214}, "words": "作用机制"}, {"probability": {"variance": 0.00829, "average": 0.965952, "min": 0.488342}, "location": {"width": 724, "top": 252, "height": 36, "left": 257}, "words": "本品为鸟嘌呤核苷类似物:对乙肝病毒(HBV)多聚酶具有抑制作用它能够通过磷酸"}, {"probability": {"variance": 0.0033, "average": 0.978372, "min": 0.663066}, "location": {"width": 765, "top": 291, "height": 38, "left": 215}, "words": "化成为具有活性的三磷酸盐,三磷酸盐在细胞内的半衰期为15小时,通过与HBV多聚酶的"}, {"probability": {"variance": 0.019304, "average": 0.932627, "min": 0.46483}, "location": {"width": 766, "top": 330, "height": 40, "left": 213}, "words": "天然底物三磷酸脱氧鸟嘌吟核苷竞争,思替卡韦三磷酸盐能抑制病毒多骤酶(逆转录酶)的"}, {"probability": {"variance": 0.013499, "average": 0.939625, "min": 0.480371}, "location": {"width": 769, "top": 369, "height": 39, "left": 209}, "words": "所有三种活性:(1)HBV多聚酶的启动;(2)前基因组mRNA逆转录负链的形成;(3) HBV DNA"}, {"probability": {"variance": 0.014377, "average": 0.941095, "min": 0.423866}, "location": {"width": 768, "top": 406, "height": 41, "left": 210}, "words": "正链的合成,恩替卡韦三磷酸盐对 HRV DNA多聚酶的抑制常数(Ki)为0.0012替卡"}, {"probability": {"variance": 0.034797, "average": 0.891915, "min": 0.36165}, "location": {"width": 770, "top": 446, "height": 40, "left": 209}, "words": "韦点磷酸盐对细胞的、B、DNA多骤酶和线粒体YDNA多聚酶抑制作用较弱,Ki值为"}, {"probability": {"variance": 0.015545, "average": 0.932252, "min": 0.607179}, "location": {"width": 100, "top": 502, "height": 22, "left": 210}, "words": "18至160uM"}, {"probability": {"variance": 3.8e-05, "average": 0.99422, "min": 0.98591}, "location": {"width": 99, "top": 565, "height": 24, "left": 206}, "words": "抗病毒活性"}, {"probability": {"variance": 0.031105, "average": 0.900497, "min": 0.352589}, "location": {"width": 725, "top": 588, "height": 39, "left": 249}, "words": "在转染了野生乙肝病毒的人类epG2细胞中,思整卡韦抑制50%病毒DNA合成所需浓"}, {"probability": {"variance": 0.043287, "average": 0.822844, "min": 0.360213}, "location": {"width": 774, "top": 620, "height": 51, "left": 202}, "words": "度(ECm)为0.00M恩替卡韦对拉米夫定耐药病毒株GH2oN)的ECm的中"}, {"probability": {"variance": 0.020555, "average": 0.930322, "min": 0.405628}, "location": {"width": 774, "top": 664, "height": 43, "left": 201}, "words": "位值是0.026M(范围0.01至0.059M),而思替卡韦对在细胞培养液中生长的型人类免"}, {"probability": {"variance": 0.018346, "average": 0.917059, "min": 0.443767}, "location": {"width": 400, "top": 709, "height": 35, "left": 201}, "words": "疫缺陷病毒(HIV)无临床相关活性(ECn>10puM"}, {"probability": {"variance": 0, "average": 0.861165, "min": 0.861165}, "location": {"width": 24, "top": 713, "height": 23, "left": 689}, "words": "3"}, {"probability": {"variance": 0.017256, "average": 0.924493, "min": 0.460456}, "location": {"width": 706, "top": 740, "height": 45, "left": 244}, "words": "每天或每周一次使用本品能降低北美土拨鼠和鸭的肝炎病毒DM承平4至81Ogm"}, {"probability": {"variance": 0.022272, "average": 0.93543, "min": 0.408693}, "location": {"width": 774, "top": 779, "height": 43, "left": 201}, "words": "对5只北美土拨鼠的长期研究表明,每周口服0.5mg/kg恩替卡韦(相当体1.0mg的剂"}, {"probability": {"variance": 0.004813, "average": 0.970715, "min": 0.55107}, "location": {"width": 767, "top": 816, "height": 43, "left": 198}, "words": "量)能将其中的3只土拨鼠的病毒DNA保持在不可测水平(病毒DNA水平<200拷贝/mL,PC"}, {"probability": {"variance": 0.016787, "average": 0.958381, "min": 0.397763}, "location": {"width": 774, "top": 855, "height": 42, "left": 198}, "words": "法)长达3年之久在任何使用该药治疗长达3年的动物中,未发现HBV多聚酶发生与替"}, {"probability": {"variance": 3.5e-05, "average": 0.995093, "min": 0.981489}, "location": {"width": 177, "top": 908, "height": 25, "left": 198}, "words": "卡韦耐药相关的变化"}, {"probability": {"variance": 0, "average": 0.999591, "min": 0.999196}, "location": {"width": 61, "top": 975, "height": 23, "left": 195}, "words": "耐药性"}, {"probability": {"variance": 0.00098, "average": 0.97444, "min": 0.922155}, "location": {"width": 80, "top": 1012, "height": 24, "left": 199}, "words": "体外研究"}, {"probability": {"variance": 0.00669, "average": 0.971571, "min": 0.516481}, "location": {"width": 714, "top": 1033, "height": 42, "left": 245}, "words": "在细胞试验中发现,拉米夫定耐药的病毒株对恩替卡韦的显型敏感性降低8至30倍"}, {"probability": {"variance": 0.011543, "average": 0.95321, "min": 0.452692}, "location": {"width": 764, "top": 1072, "height": 42, "left": 194}, "words": "如果乙肝病毒多聚酶本来就存在对拉米夫定耐药的氨基酸置换(rtL180M和/或rtM204V/l)"}, {"probability": {"variance": 0.018889, "average": 0.932779, "min": 0.37307}, "location": {"width": 766, "top": 1110, "height": 43, "left": 193}, "words": "再加上rtT184,rt202或rtM250位点的置换变异,或者在以上两种变异同时发生的基础上"}, {"probability": {"variance": 0.009437, "average": 0.967457, "min": 0.416472}, "location": {"width": 764, "top": 1148, "height": 44, "left": 193}, "words": "无论是否出现rt169的置换变异,都会造成对替卡韦的显型敏感性降低更多(>70倍)"}, {"probability": {"variance": 0.016631, "average": 0.897554, "min": 0.680344}, "location": {"width": 81, "top": 1204, "height": 24, "left": 196}, "words": "临床研究"}, {"probability": {"variance": 0.031746, "average": 0.914628, "min": 0.371333}, "location": {"width": 773, "top": 1224, "height": 46, "left": 194}, "words": "获类药物初治患者:81%的核苷类药物初治病人在口服思替卡韦0.5g/748周后,病毒"}, {"probability": {"variance": 0.014655, "average": 0.926153, "min": 0.447948}, "location": {"width": 775, "top": 1263, "height": 46, "left": 192}, "words": "载量达到300拷/mL。 Hbeag阳性(AI463022研究,n=219)或 HBEAG阴性(A463027研"}, {"probability": {"variance": 0, "average": 0.996561, "min": 0.996561}, "location": {"width": 23, "top": 1325, "height": 22, "left": 193}, "words": "究"}, {"probability": {"variance": 0.000404, "average": 0.988139, "min": 0.922799}, "location": {"width": 715, "top": 1304, "height": 42, "left": 251}, "words": "211)的核苷类药物初治患者在治疗48周后,基因型分析结果表明 HBV DNA多聚酶的"}, {"probability": {"variance": 0.010683, "average": 0.950191, "min": 0.623798}, "location": {"width": 775, "top": 1339, "height": 44, "left": 191}, "words": "基因没有发生与表型耐药相关的基因型变异,在AI463022研究中,有2名病人发生了病毒"}, {"probability": {"variance": 0.013606, "average": 0.957626, "min": 0.404287}, "location": {"width": 777, "top": 1375, "height": 44, "left": 191}, "words": "学反弹( HBV DNA从最低点上升1个10g),但没有发现与恩替卡耐药相关的基因型或表型"}, {"probability": {"variance": 0.008877, "average": 0.889513, "min": 0.795295}, "location": {"width": 41, "top": 1432, "height": 23, "left": 189}, "words": "证据"}], "language": 3}